---
title: "Tarsus Pharmaceuticals (NASDAQ:TARS) Now Covered by Oppenheimer"
description: "Oppenheimer has initiated coverage on Tarsus Pharmaceuticals (NASDAQ:TARS), assigning an \"outperform\" rating and a price target of $75.00, indicating a potential upside of 76.10% from its previous clo"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/242799551.md"
published_at: "2025-06-02T14:22:06.000Z"
---

# Tarsus Pharmaceuticals (NASDAQ:TARS) Now Covered by Oppenheimer

> Oppenheimer has initiated coverage on Tarsus Pharmaceuticals (NASDAQ:TARS), assigning an "outperform" rating and a price target of $75.00, indicating a potential upside of 76.10% from its previous close. Other analysts have varied opinions, with Barclays lowering their target to $60.00 and Goldman Sachs raising it to $51.00. The stock currently has a consensus rating of "Moderate Buy" with an average target of $66.67. Tarsus reported a revenue of $78.34 million for the last quarter, exceeding estimates, and has a market cap of $1.79 billion.

Oppenheimer initiated coverage on shares of Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) in a note issued to investors on Monday. The brokerage set an "outperform" rating and a $75.00 price target on the stock. Oppenheimer's target price indicates a potential upside of 76.10% from the company's previous close.

Get **Tarsus Pharmaceuticals** alerts:

Other equities research analysts also recently issued reports about the stock. Barclays reduced their price target on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. The Goldman Sachs Group upped their target price on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a research note on Monday, May 5th. Wall Street Zen downgraded shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Guggenheim increased their price objective on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Finally, HC Wainwright raised shares of Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 price objective on the stock in a research report on Tuesday, May 27th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $66.67.

**Read Our Latest Report on TARS**

## Tarsus Pharmaceuticals Price Performance

TARS traded down $0.36 on Monday, reaching $42.59. 43,739 shares of the company's stock were exchanged, compared to its average volume of 699,781. The stock has a market cap of $1.79 billion, a PE ratio of -11.21 and a beta of 0.94. Tarsus Pharmaceuticals has a twelve month low of $20.08 and a twelve month high of $57.28. The stock's fifty day moving average price is $46.93 and its 200-day moving average price is $48.96. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.05. The company had revenue of $78.34 million for the quarter, compared to analyst estimates of $72.50 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. Sell-side analysts expect that Tarsus Pharmaceuticals will post -3.17 EPS for the current year.

## Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, CEO Bobak R. Azamian sold 7,131 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $330,093.99. Following the completion of the sale, the chief executive officer now owns 70,720 shares of the company's stock, valued at $3,273,628.80. This represents a 9.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Bryan Wahl sold 3,084 shares of the firm's stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $50.11, for a total transaction of $154,539.24. Following the transaction, the general counsel now directly owns 51,712 shares of the company's stock, valued at approximately $2,591,288.32. This represents a 5.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 32,542 shares of company stock valued at $1,581,173 over the last quarter. Corporate insiders own 8.25% of the company's stock.

## Hedge Funds Weigh In On Tarsus Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Crowley Wealth Management Inc. acquired a new stake in Tarsus Pharmaceuticals in the fourth quarter valued at approximately $25,000. GF Fund Management CO. LTD. acquired a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter valued at $44,000. Amalgamated Bank boosted its stake in shares of Tarsus Pharmaceuticals by 30.1% in the 1st quarter. Amalgamated Bank now owns 1,274 shares of the company's stock valued at $65,000 after purchasing an additional 295 shares in the last quarter. Quarry LP acquired a new position in Tarsus Pharmaceuticals during the 4th quarter worth about $166,000. Finally, AlphaQuest LLC acquired a new stake in shares of Tarsus Pharmaceuticals in the 1st quarter valued at approximately $189,000. Institutional investors and hedge funds own 90.01% of the company's stock.

## About Tarsus Pharmaceuticals

(Get Free Report)

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

## Featured Stories

-   Five stocks we like better than Tarsus Pharmaceuticals
-   Manufacturing Stocks Investing
-   Buy The Dip in Okta, There’s Nothing Wrong With the Outlook
-   The Most Important Warren Buffett Stock for Investors: His Own
-   Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern
-   What is the NASDAQ Stock Exchange?
-   3 High-Risk, High-Reward Gold ETFs You May Be Missing

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

## Should You Invest $1,000 in Tarsus Pharmaceuticals Right Now?

Before you consider Tarsus Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.

While Tarsus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [TARS.US - Tarsus Pharmaceuticals](https://longbridge.com/en/quote/TARS.US.md)
- [GS.US - Goldman Sachs](https://longbridge.com/en/quote/GS.US.md)
- [BCS.US - Barclays](https://longbridge.com/en/quote/BCS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Tarsus Pharmaceuticals 的首席人力资源官 Dianne C. Whitfield 报告了普通股的出售 | Dianne C. Whitfield，Tarsus Pharmaceuticals Inc. 的首席人力资源官，已报告处置该公司的普通股。完整的文件可通过提供的链接获取。此新闻简报由公共技术生成，仅供信息参考，不应被视为财务、投资或法律建 | [Link](https://longbridge.com/en/news/271698080.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
